Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function.

W J Thompson1

  • 1Department of Pharmacology, University of South Alabama College of Medicine, Mobile.

Pharmacology & Therapeutics
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens.

BMC cancer·2021
Same author

Induction of zinc-finger proliferation 1 expression in non-myelinating Schwann cells after denervation.

Neuroscience·2008
Same author

Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme.

The Journal of cell biology·2001
Same author

Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.

The Journal of pharmacology and experimental therapeutics·2001
Same author

Seeing is believing: GFP transgenics illuminate synapse elimination.

Neuron·2001
Same author

Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.

Cancer research·2001
Same journal

Nipocalimab and other FcRn blockers in neuromuscular disorders.

Pharmacology & therapeutics·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
Same journal

A-type potassium channels in pain signaling: Fundamental mechanisms and pathophysiological roles.

Pharmacology & therapeutics·2026
See all related articles

This review explores cyclic nucleotide phosphodiesterase (CN PDE) enzymology and pharmacology, recommending isozyme nomenclature consolidation. Understanding CN PDE isozyme localization and function is crucial for developing new therapeutic inhibitors.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Molecular Biology

Background:

  • Cyclic nucleotide phosphodiesterases (CN PDEs) are crucial enzymes regulating intracellular cyclic nucleotide levels.
  • Recent advances in CN PDE enzymology and pharmacology highlight the complexity of these enzymes.
  • Existing isozyme nomenclature requires consolidation for clarity.

Purpose of the Study:

  • To review the complex enzymology of CN PDEs in relation to recent pharmacological advances.
  • To recommend a consolidated nomenclature for CN PDE isozymes.
  • To emphasize the importance of subcellular localization and substrate specificity in CN PDE function.

Main Methods:

  • Literature review of CN PDE enzymology and pharmacology.
  • Analysis of isozyme nomenclature and functional roles.

Related Experiment Videos

  • Discussion of existing and potential CN PDE inhibitors.

    • Main Results:

    • Consolidation of isozyme nomenclature to proposed family designations is recommended.
    • Subcellular localization and cyclic GMP roles are critical for understanding CN PDE isozyme function.
    • Several CN PDE inhibitors show potential for experimental and clinical use.

    Conclusions:

    • Standardized CN PDE nomenclature is essential for research and clinical applications.
    • Understanding isozyme-specific functions is key to targeted therapeutic development.
    • A range of CN PDE inhibitors are available for further investigation.